Propionic acidemia (PA) occurs because of mutations in the PCCA or PCCB genes encoding the two subunits of propionyl-CoA carboxylase, a pivotal enzyme in the breakdown of certain amino acids and odd-chain fatty acids. There is no cure for PA, but dietary protein restriction and liver transplantation can attenuate its symptoms. We show here that a single intravenous injection of adeno-associated virus 2/8 (AAV8) or AAVrh10 expressing PCCA into PA hypomorphic mice decreased systemic propionylcarnitine and methyl citrate for up to 1.5 years. However, long-term phenotypic correction was always better in male mice. AAV-mediated PCCA expression was similar in most tissues in males and females at early time points and differed only in the liver. Over 1.5 years, luciferase and PCCA expression remained elevated in cardiac tissue for both sexes. In contrast, transgene expression in the liver and skeletal muscles of female, but not male, mice waned—suggesting that these tissues were major sinks for systemic phenotypic correction. These data indicate that single systemic intravenous therapy by AAV vectors can mediate long-term phenotype correction for PA. However, tissue-specific loss of expression in females reduces efficacy when compared with males. Whether similar sex-biased AAV effects occur in human gene therapy remains to be determined.
BaumgartnerMR, HorsterF, Dionisi-ViciC, et al.Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis, 2014; 9:130.
3.
PenaL, FranksJ, ChapmanKA, et al.Natural history of propionic acidemia. Mol Genet Metab, 2012; 105:5–9.
4.
PettenuzzoLF, SchuckPF, FontellaF, et al.Ascorbic acid prevents cognitive deficits caused by chronic administration of propionic acid to rats in the water maze. Pharmacol Biochem Behav, 2002; 73:623–629.
5.
KolkerS, BurgardP, SauerSW, et al.Current concepts in organic acidurias: understanding intra- and extracerebral disease manifestation. J Inherit Metab Dis, 2013; 36:635–644.
6.
SchwabMA, SauerSW, OkunJG, et al.Secondary mitochondrial dysfunction in propionic aciduria: a pathogenic role for endogenous mitochondrial toxins. Biochem J, 2006; 398:107–112.
7.
Ah MewN, MccarterR, DaikhinY, et al.N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia. Pediatrics, 2010; 126:e208–e214.
8.
TuchmanM, CaldovicL, DaikhinY, et al.N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. Pediatr Res, 2008; 64:213–217.
9.
SperlW, MurrC, SkladalD, et al.Odd-numbered long-chain fatty acids in propionic acidaemia. Eur J Pediatr, 2000; 159:54–58.
10.
Cheema-DhadliS, LeznoffCC, HalperinML. Effect of 2-methylcitrate on citrate metabolism: implications for the management of patients with propionic acidemia and methylmalonic aciduria. Pediatr Res, 1975; 9:905–908.
11.
TurgeonCT, MageraMJ, CuthbertCD, et al.Determination of total homocysteine, methylmalonic acid, and 2-methylcitric acid in dried blood spots by tandem mass spectrometry. Clin Chem, 2010; 56:1686–1695.
12.
BrandtIK, HsiaYE, ClementDH, et al.Propionicacidemia (ketotic hyperglycinemia): dietary treatment resulting in normal growth and development. Pediatrics, 1974; 53:391–395.
13.
TouatiG, ValayannopoulosV, MentionK, et al.Methylmalonic and propionic acidurias: management without or with a few supplements of specific amino acid mixture. J Inherit Metab Dis, 2006; 29:288–298.
14.
YannicelliS, AcostaPB, VelazquezA, et al.Improved growth and nutrition status in children with methylmalonic or propionic acidemia fed an elemental medical food. Mol Genet Metab, 2003; 80:181–188.
15.
SuttonVR, ChapmanKA, GropmanAL, et al.Chronic management and health supervision of individuals with propionic acidemia. Mol Genet Metab, 2012; 105:26–33.
16.
ThompsonGN, ChalmersRA. Increased urinary metabolite excretion during fasting in disorders of propionate metabolism. Pediatr Res, 1990; 27:413–416.
17.
RelaM, MuiesanP, AndreaniP, et al.Auxiliary liver transplantation for metabolic diseases. Transplant Proc, 1997; 29:444–445.
18.
SchlenzigJS, Poggi-TravertF, LaurentJ, et al.Liver transplantation in two cases of propionic acidaemia. J Inherit Metab Dis, 1995; 18:448–461.
19.
YorifujiT, MuroiJ, UematsuA, et al.Living-related liver transplantation for neonatal-onset propionic acidemia. J Pediatr, 2000; 37:572–574.
20.
YorifujiT, KawaiM, MamadaM, et al.Living-donor liver transplantation for propionic acidaemia. J Inherit Metab Dis, 2004; 27:205–210.
21.
BarshesNR, VanattaJM, PatelAJ, et al.Evaluation and management of patients with propionic acidemia undergoing liver transplantation: a comprehensive review. Pediatr Transplant, 2006; 10:773–781.
22.
GuenzelAJ, HofherrSE, HillestadM, et al.Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing. Mol Ther, 2013; 21:1316–1323.
23.
MiyazakiT, OhuraT, KobayashiM, et al.Fatal propionic acidemia in mice lacking propionyl-CoA carboxylase and its rescue by postnatal, liver-specific supplementation via a transgene. J Biol Chem, 2001; 276:35995–35999.
24.
CampeauE, DesviatLR, LeclercD, et al.Structure of the PCCA gene and distribution of mutations causing propionic acidemia. Mol Genet Metab, 2001; 74:238–247.
25.
GuenzelAJ, KrausJP, MaternD, et al.Long-term sex-biased correction of circulating propionic acidemia disease markers by adeno-associated virus vectors. Hum Gene Ther, 2014 [Epub ahead of print].
26.
LockM, AlviraM, VandenbergheLH, et al.Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther, 2010; 21:1259–1271.
27.
TurgeonC, MageraMJ, AllardP, et al.Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. Clin Chem, 2008:54:657–664.
28.
JiangH, RaoKS, YeeVC, et al.Characterization of four variant forms of human propionyl-CoA carboxylase expressed in Escherichia coli. J Biol Chem, 2005; 280:27719–27727.
29.
ChandlerRJ, ChandrasekaranS, Carrillo-CarrascoN, et al.Adeno-associated virus serotype 8 gene transfer rescues a neonatal lethal murine model of propionic acidemia. Hum Gene Ther, 2011; 22:477–481.
30.
HofherrSE, SenacJS, ChenCY, et al.Short-term rescue of neonatal lethality in a mouse model of propionic acidemia by gene therapy. Hum Gene Ther, 2009; 20:169–180.
31.
DavidoffAM, NgCY, ZhouJ, et al.Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood, 2003; 102:480–488.
32.
PanedaA, VanrellL, MauleonI, et al.Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders. Hum Gene Ther, 2009; 20:908–917.
33.
DaneAP, CunninghamSC, GrafNS, et al.Sexually dimorphic patterns of episomal rAAV genome persistence in the adult mouse liver and correlation with hepatocellular proliferation. Mol Ther, 2009; 17:1548–1554.
34.
BergmannO, BhardwajRD, BernardS, et al.Evidence for cardiomyocyte renewal in humans. Science, 2009; 324:98–102.
35.
MarkleJG, FrankDN, Mortin-TothS, et al.Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science, 2013; 339:1084–1088.
36.
De KeyzerY, ValayannopoulosV, BenoistJF, et al.Multiple OXPHOS deficiency in the liver, kidney, heart, and skeletal muscle of patients with methylmalonic aciduria and propionic aciduria. Pediatr Res, 2009; 66:91–95.
37.
FragakiK, CanoA, BenoistJF, et al.Fatal heart failure associated with CoQ10 and multiple OXPHOS deficiency in a child with propionic acidemia. Mitochondrion, 2011; 11:533–536.
38.
MardachR, VerityMA, CederbaumSD. Clinical, pathological, and biochemical studies in a patient with propionic acidemia and fatal cardiomyopathy. Mol Genet Metab, 2005; 85:286–290.
39.
BhanAK, BrodyC. Propionic acidemia: a rare cause of cardiomyopathy. Congest Heart Fail, 2001; 7:218–219.
40.
KrausJP, SpectorE, VeneziaS, et al.Mutation analysis in 54 propionic acidemia patients. J Inherit Metab Dis, 2012; 35:51–63.
41.
MortonDH, DonnellyP, DuffyA, et al.Cardiomyopathy is common in the propionic acidemia variant PCCB c.1606A>G and can be prevented & reversed by metabolic therapy. Mol Genet Metab, 2014; 111:262–263.
42.
DonsanteA, MillerDG, LiY, et al.AAV vector integration sites in mouse hepatocellular carcinoma. Science, 2007; 317:477.
43.
DonsanteA, VoglerC, MuzyczkaN, et al.Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther, 2001; 8:1343–1346.
44.
MillerDG, TrobridgeGD, PetekLM, et al.Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol, 2005; 79:11434–11442.
45.
NakaiH, WuX, FuessS, et al.Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol, 2005; 79:3606–3614.
46.
ChandlerRJ, LaFaveMC, VarshneyGK, et al.Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest, 2015 [Epub ahead of print] DOI: 10.1172/JCI79213
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
